Results 71 to 80 of about 12,730,863 (301)

Differentiation of secondary involvement of the breast by lymphoreticular malignancy from fibroadenoma using ultrasound elastography: A report of two cases

Indian Journal of Radiology and Imaging, 2017
Extramedullary lymphoma infiltration of the breast by lymphoblastic lymphoma is very rare and most cases are of B-cell lineage; T-cell neoplasms represent less than 10% of all breast lymphomas.
Eren Abdulkadir, Ertan Gulhan, Sila Ulus
doaj   +1 more source

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care

American Journal of Hematology, EarlyView.
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali, Grace Elsey, Kayla Fulginiti, Zanette Kanani‐Bradley, Holly R. Kubaney, Sandra Kurtin, Theresa Nguyen, Jennifer Turchina, Charlotte B. Wagner   +8 more
wiley   +1 more source

Repression of nuclear lamin A and C gene expression in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells.

Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis, 1990
The lamins A, B and C which are differentially expressed during ontogenesis and differentiation are karyoskeletal proteins forming a polymeric meshwork at the inner nuclear membrane. Using Northern blot analyses we investigated the steady state levels of
B. Stadelmann, Edward W. Khandjian, Andreas Hirt, A. R. Lüthy, R. Weil, H.N.R. Wagner   +5 more
semanticscholar   +1 more source

Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues [PDF]

Pediatric Blood & Cancer, 2016
Recurrent genomic changes in B-lymphoblastic leukemia (B-ALL) identified by genome-wide single-nucleotide polymorphism (SNP) microarray analysis provide important prognostic information, but gene copy number analysis of its rare lymphoma counterpart, B-lymphoblastic lymphoma (B-LBL), is limited by the low incidence and lack of fresh tissue for genomic ...
Meyer, Julia A., Zhou, Delu, Mason, Clinton C., Downie, Jonathan M., Rodic, Vladimir, Abromowitch, Minnie, Wistinghausen, Birte, Termuhlen, Amanda M., Angiolillo, Anne L., Perkins, Sherrie L., Lones, Mark A., Barnette, Phillip, Schiffman, Joshua D., Miles, Rodney R.   +13 more
openaire   +3 more sources

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, EarlyView.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source

Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma : endpoints of a spectrum of one disease? [PDF]

, 2013
In contrast to the commonly indolent clinical behavior of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T cell/histiocyte rich large B cell lymphoma (THRLBCL) is frequently diagnosed in advanced clinical stages and has a poor prognosis ...
Benjamin Rengstl, Sebastian Newrzela, Randy Gascoyne, Xavier Sagaert (482298), Xavier Sagaert, Hartmann, Sylvia, Martin-Leo Hansmann, Claudia Döring, Küppers, Ralf, Chris de Wolf-Peeters, Fabio Facchetti, Ralf Küppers, Fabio Facchetti (376587), Sylvia Hartmann, Rengstl, Benjamin, Hansmann, Martin-Leo, Christian Steidl, Sagaert, Xavier, Martin-Leo Hansmann (260067), Tousseyn, Thomas, Christian Steidl (482300), Ralf Küppers (260072), Thomas Tousseyn (482297), Chris de Wolf-Peeters (482299), Steidl, Christian, Claudia Döring (474984), Ponzoni, Maurilio, Randy Gascoyne (482301), Jakobus, Christina, Wolf-Peeters, Chris de, Benjamin Rengstl (482295), Sebastian Newrzela (482296), Gascoyne, Randy, Maurilio Ponzoni (126480), Döring, Claudia, Thomas Tousseyn, Christina Jakobus (482294), Christina Jakobus, Facchetti, Fabio, Sylvia Hartmann (260069), Newrzela, Sebastian, Maurilio Ponzoni   +41 more
core   +2 more sources

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Frontiers in Oncology
Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm ...
Mengci Hu, Wenzhe Li, Pan Li, Jie Tan, Ya Wang, Ya Wang   +5 more
doaj   +1 more source

Histiocytic Sarcoma Following B-Lymphoblastic Leukemia/Lymphoma

American Journal of Clinical Pathology, 2019
AbstractObjectivesRare cases of clonally related histiocytic sarcoma (HS) following B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) have been reported to date.MethodsWe present a patient with HS, which appeared as a breast mass 12 months after the initial diagnosis of B-ALL.ResultsBoth HS and the B-ALL shared IGH-MYC and IGK gene rearrangements.
Julia T Geyer, Nuri Yigit, Ayako Miyaguchi, Shuhua Cheng, Joseph Casano, Susan Mathew, Pinkal Desai, Usama Gergis, Wayne Tam   +8 more
openaire   +2 more sources

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source